Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 CVXGA1 Intranasal COVID-19 Vaccine Trial
NCT04954287Phase 1Completed
- Sponsor
- CyanVac LLC
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CVXGA in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by CyanVac LLC. Primary endpoints: Solicited Adverse Events and Unsolicited Adverse Events. Started Aug 2021; status: completed.
02
Drugs
CVXGA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04954287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954287.